Please use this identifier to cite or link to this item:
http://dx.doi.org/10.25673/115506
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lehrke, Michael | - |
dc.contributor.author | Vogt, Anja | - |
dc.contributor.author | Schettler, Volker | - |
dc.contributor.author | Girndt, Matthias | - |
dc.contributor.author | Fraass, Uwe | - |
dc.contributor.author | Tabbert-Zitzler, Anja | - |
dc.contributor.author | Bridges, Ian | - |
dc.contributor.author | Dhalwani, Nafeesa N. | - |
dc.contributor.author | Ray, Kausik K. | - |
dc.date.accessioned | 2024-03-26T08:24:43Z | - |
dc.date.available | 2024-03-26T08:24:43Z | - |
dc.date.issued | 2024 | - |
dc.identifier.uri | https://opendata.uni-halle.de//handle/1981185920/117460 | - |
dc.identifier.uri | http://dx.doi.org/10.25673/115506 | - |
dc.description.abstract | Introduction: Low-density lipoprotein cholesterol (LDL-C) is among the most important modifiable risk factors for cardiovascular disease. In very high-risk patients, the European Society of Cardiology/European Atherosclerosis Society guidelines recommend attaining LDL-C < 55 mg/dL. In the German cohort of the observational HEYMANS study, we aimed to describe the clinical characteristics and LDL-C control among patients initiating evolocumab. Methods: Data was collected between 09/2016 and 05/2021 for ≤ 6 months before (retrospectively) and ≤ 30 months after evolocumab initiation (prospectively). Patient characteristics, lipid-lowering therapy (LLT), lipid values, evolocumab use, and safety were collected. Results: Of 380 enrolled patients, 93% received evolocumab in secondary prevention and 69% had a history of statin intolerance. At study baseline, 49% did not receive any statins and LDL-C was very high (145 mg/dL). Use of evolocumab decreased LDL-C by a median of 53% within 3 months and remained stable thereafter, despite mainly unchanged background LLT. Overall, 59% attained an LDL-C level < 55 mg/dL (69% with, 49% without LLT). Persistence to evolocumab was 90.6% in months 1–12 and 93.5% in months 13–30. Adverse drug reactions were reported in 8% of patients. Conclusion: Data from the German HEYMANS cohort corroborate previous reports on evolocumab effectiveness and safety in clinical practice. Evolocumab initiation was associated with a rapid and sustained LDL-C reduction. Persistence with evolocumab was high. Our finding that patients receiving an evolocumab/LLT combination are more likely to attain the LDL-C goal than those receiving evolocumab alone corroborates previous data showing the importance of using highly intensive therapy. Graphical abstract available for this article. | eng |
dc.language.iso | eng | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | - |
dc.subject.ddc | 610 | - |
dc.title | Evolocumab-based LDL-C management in high and very high cardiovascular risk patients in German clinical practice : the HEYMANS study | eng |
dc.type | Article | - |
local.versionType | publishedVersion | - |
local.bibliographicCitation.journaltitle | Advances in therapy | - |
local.bibliographicCitation.volume | 41 | - |
local.bibliographicCitation.pagestart | 1184 | - |
local.bibliographicCitation.pageend | 1200 | - |
local.bibliographicCitation.publishername | Springer Healthcare Communications | - |
local.bibliographicCitation.publisherplace | Tarporley | - |
local.bibliographicCitation.doi | 10.1007/s12325-023-02757-x | - |
local.openaccess | true | - |
dc.identifier.ppn | 1884329039 | - |
cbs.publication.displayform | 2024 | - |
local.bibliographicCitation.year | 2024 | - |
cbs.sru.importDate | 2024-03-26T08:24:04Z | - |
local.bibliographicCitation | Enthalten in Advances in therapy - Tarporley : Springer Healthcare Communications, 2000 | - |
local.accessrights.dnb | free | - |
Appears in Collections: | Open Access Publikationen der MLU |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
s12325-023-02757-x.pdf | 1.35 MB | Adobe PDF | ![]() View/Open |